A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
A study to assess the effects of Sativex treatment on spasticity in a population of children
and adolescents aged from 8 to 18 years with cerebral palsy or traumatic central nervous
system injury. Efficacy (ability to improve symptoms), safety and tolerability will be
monitored.